The current political battle over gender-affirming care isn’t simply a debate about healthcare access; it’s a stark demonstration of how politically motivated misrepresentation of basic biological science can rapidly erode the foundations of evidence-based medicine for all Americans. While headlines focus on restrictions to care for transgender youth, the underlying issue – a deliberate distortion of the relationship between sex and gender – poses a broader threat to patient autonomy and the integrity of scientific understanding. The US Department of Health and Human Services (HHS) is currently finalizing a rule that would block Medicaid and Medicare payments for gender-affirming care for those under 18, a policy shift prompting major medical centers like Mount Sinai, NYU Langone, and the University of Utah Health to discontinue their pediatric programs. This isn’t a measured policy adjustment; it’s a consequence of a fundamental misunderstanding – and deliberate mischaracterization – of human biology.
The core of the conflict lies in the conflation of “sex” and “gender,” a distinction the World Health Organization explicitly warns against. Sex, typically defined by “physical and physiological features” – chromosomes, hormone expression, anatomy – is often presented as a rigid binary. However, this simplification ignores the inherent complexity of biological variation. As Jess McLaughlin, an assistant professor of biological sciences at the University of Alaska Anchorage, explains, “These oversimplified understandings of the biology of sex are being used to back up transgender legislation and federal policy.” The administration’s claims of “immutable” biological sex, articulated in an executive order targeting “gender ideology extremism,” are demonstrably flawed. The very notion of defining sex at conception, based on reproductive cells, falls apart under scrutiny. Fertilized eggs are initially single-celled and don’t possess the differentiated reproductive cells the order claims to identify. Furthermore, the development of sex characteristics doesn’t occur until months later in gestation, and fully matures at puberty.
This isn’t merely a semantic argument. The HHS order’s use of the term “sex-rejecting procedures” – a phrase originating with a conservative religious group in April 2025 – reveals a deeply ideological framing of medical care. It implies a rejection of inherent biological traits, ignoring the reality that gender identity is a complex interplay of biological, psychological, and social factors. The administration’s attempt to define sex, and subsequently restrict care based on that definition, has stumbled repeatedly. The existence of intersex individuals – those with natural variations in chromosomes and anatomy – is conveniently omitted from the narrative. As McLaughlin points out, “One of the core things that we’re running up against is: what on earth are we even talking about with ‘sex’? Do we mean chromosomes? Because that doesn’t often match.” The reality is that chromosomal variations are far more common than many realize, with combinations like XXY and instances of differing sex chromosomes within different cells of the same individual.
Drawn from The Guardian.
The consequences of this distorted science extend beyond the immediate impact on transgender individuals. Jey McCreight, founder of Beyond X&Y and a doctoral degree holder in human genomics, argues that this is “fundamentally coming from a broader attempt to dismantle science and expertise and truth.” The administration’s actions, including halting gender-affirming care in correctional facilities and restricting access to clothing and hormones for trans inmates, are part of a larger pattern. McCreight warns that this sets a dangerous precedent, potentially impacting access to other forms of care, like abortion and vaccines, which have also been targeted by the administration. Cisgender men within the Veterans Affairs system have already reported difficulty receiving treatment for breast cancer due to the new HHS rules, demonstrating the ripple effect of these policies. The administration’s rhetoric, focusing on the perceived “visibility” of sex characteristics, ignores the fact that these traits are often malleable through medical interventions – a point McLaughlin emphasizes.
The recent focus on the cost of gender-affirming surgeries, exemplified by Dr. Mehmet Oz’s claim of $150,000 for phalloplasty in youth, further illustrates the misinformation driving this debate. McCreight found no evidence to support this claim, noting that such procedures are rarely performed on minors and that breast reductions and augmentations are far more common among cisgender teens. Moreover, denying potentially life-saving care to transgender youth, as this policy effectively does, carries severe risks, ranging from increased mental health struggles to a heightened risk of suicide. The administration’s broader agenda, as McCreight articulates, is “a larger movement to try to make people conform to what’s seen as an ideal, but that ideal really comes from white Christian nationalism, not scientific reality.”
Looking ahead, the critical question isn’t simply whether these policies will be upheld in court, but whether the deliberate erosion of scientific integrity will continue. We should be watching for a parallel dismantling of research funding and a further politicization of scientific advisory boards. If the administration continues to prioritize ideology over evidence, what safeguards will remain to protect the integrity of healthcare – and public health – for all Americans?
